Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma.

ABSTRACT:

Background

Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking.

Methods

Patient performance status, tumour burden (determined by the presence or absence of liver metastases), plasma protein biomarkers (CA19-9, albumin, C-reactive protein and neutrophils) and circulating tumour DNA (ctDNA) were assessed in 146 patients with metastatic PDAC prior to starting either concomitant or sequential nab-paclitaxel + gemcitabine chemotherapy in the SIEGE randomised prospective clinical trial, as well as during the first 8 weeks of treatment. Correlations were made with objective response, death within 1 year and overall survival (OS).

Results</

SUBMITTER: Dayimu A 

PROVIDER: S-EPMC10133256 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature